Psychedelics for Alcoholism

From Molecule to Medicine - The Clinical Trial Pathway

January 26, 2022

Clearmind’s Management Team Explained the Process Required by the FDA to Approve Clearmind’s Patented MEAI Molecule as a Medicine for Treating Alcohol Use Disorder and Binge Drinking


Adi Zuloff-Shani, PhD

Clearmind's Chief Executive Officer

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

Clearmind's VP of Business Development

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.

Amit Schwartz, MSc

Clearmind's Director of R&D

Amit has a M.Sc. Degree in Biology from the Faculty of Life Sciences in Bar-Ilan University, Israel. He has also been published on multiple occasions. His research was done in the Neuropsychopharmacology lab, under the supervision of Professor Gal Yadid, who’s on Clearmind’s Scientific Advisory Board.


Shannon Smadella

Clearmind's Community Development

Shannon has interviewed some of the most prominent leaders, innovators, scientists, doctors and luminaries in the psychedelic space. She was the host of Seasons 1 & 2 of ‘Examining The Psychedelic Renaissance’ with MAPS Canada. Shannon has researched, observed, coached and trained in excess of 5,000 individuals in sales, marketing, and business management and continues to help people through her company Insight Global, and enjoys interviewing leaders in the health and wellness field through her podcast ‘Dialed In’.